



ELIGIBLE NZ EMPLOYEES ISSUED WITH ARX SHARES

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'Aroa' or the 'Company') is pleased to announce it has made a share issue under its New Zealand Employee Tax Exempt Share Plan.

In recognition of their continuing contribution to the Company, eligible New Zealand permanent employees have received a discretionary issue of up to NZ\$2,500 worth of new fully paid ordinary shares in the Company (Shares) for nil monetary consideration (Offer). The Offer has been made under and in accordance with the Company's Employee Tax Exempt Share Plan.

The issue price for these new Shares is the 5-day VWAP of ARX shares on the ASX for the period 20-27 January 2026. The Shares were issued on 29 January 2026 (Issue Date). The Shares are subject to a three-year restriction period from the Issue Date.

The Company has issued a total of 442,961 new Shares. An Appendix 2A follows.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for <i>everybody</i>'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contact

investor@aroa.com